Plain-English translation of NCT06629584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for people with chronic myeloid leukemia (a blood cancer) whose disease has not responded adequately to their first treatment. Researchers want to see if this medication can help shrink the cancer and keep it under control. The study will follow you for up to 2 years to measure how well the treatment works and how safe it is.
Some patients don't respond well to standard first-line treatments for chronic myeloid leukemia, and doctors need better options for these patients. This trial is testing whether this medication can be an effective second-line choice.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily as a continuous treatment for cycles of 28 days over 2 years. Throughout the study, you'll have regular blood tests to monitor how well the treatment is working and to check for side effects. You'll also be asked to complete questionnaires about your quality of life and symptoms, and researchers will track how your disease responds to the treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Novartis
Enrollment target
~40 participants
Started
February 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ghayas Issa, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.